Literature DB >> 12685519

Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002.

J L Rapoport1, G Inoff-Germain.   

Abstract

Since the positive effects of stimulants on disruptive behavior were described (Bradley & Bowen, 1941), further pediatric studyhas been limited almost exclusively to samples of hyperkinetic school-age children. Because these agents normally were viewed as arousing in their effects on the central nervous system, but were calming in their therapeutic effects on these children, stimulant effects on Attention Deficit Disorder (ADD) were interpreted as being 'paradoxical.' Investigation of effects in normal children and adolescents and in those with disorders unrelated to Attention-Deficit/Hyperactivity Disorder (ADHD), as well as in young adult samples, however, indicate that stimulants appear to have similar behavioral effects in normal and in hyperactive children. This brief report is an update (as of August 2002) on studies of stimulants in ADHD and normal children, with particular focus on MPH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12685519     DOI: 10.1177/070674370200601s07

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  21 in total

Review 1.  Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder.

Authors:  Craig W Berridge; David M Devilbiss
Journal:  Biol Psychiatry       Date:  2010-09-26       Impact factor: 13.382

2.  Effects of dopamine D1 receptor blockade in the prelimbic prefrontal cortex or lateral dorsal striatum on frontostriatal function in Wistar and Spontaneously Hypertensive Rats.

Authors:  Jamie M Gauthier; David H Tassin; Linda P Dwoskin; Kathleen M Kantak
Journal:  Behav Brain Res       Date:  2014-04-19       Impact factor: 3.332

3.  D-amphetamine improves attention performance in adolescent Wistar, but not in SHR rats, in a two-choice visual discrimination task.

Authors:  Jean-Charles Bizot; Nicolas Cogrel; Fabienne Massé; Virgile Chauvin; Léa Brault; Sabrina David; Fabrice Trovero
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

4.  Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates.

Authors:  Kathryn E Gill; Peter J Pierre; James Daunais; Allyson J Bennett; Susan Martelle; H Donald Gage; James M Swanson; Michael A Nader; Linda J Porrino
Journal:  Neuropsychopharmacology       Date:  2012-07-18       Impact factor: 7.853

5.  The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex.

Authors:  Amy F T Arnsten
Journal:  J Pediatr       Date:  2009-05-01       Impact factor: 4.406

Review 6.  Personal reflections on observational and experimental research approaches to childhood psychopathology.

Authors:  Judith L Rapoport
Journal:  J Child Psychol Psychiatry       Date:  2008-11-01       Impact factor: 8.982

Review 7.  The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex.

Authors:  Robert C Spencer; David M Devilbiss; Craig W Berridge
Journal:  Biol Psychiatry       Date:  2014-09-28       Impact factor: 13.382

Review 8.  Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction.

Authors:  Amy F T Arnsten
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness.

Authors:  David M Devilbiss; Craig W Berridge
Journal:  Biol Psychiatry       Date:  2008-06-30       Impact factor: 13.382

Review 10.  Differential cognitive actions of norepinephrine a2 and a1 receptor signaling in the prefrontal cortex.

Authors:  Craig W Berridge; Robert C Spencer
Journal:  Brain Res       Date:  2015-11-22       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.